Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has received a consensus rating of “Hold” from the six research firms that are currently covering the firm. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $2.50.
Separately, Zacks Investment Research cut shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 4th.
“Marinus Pharmaceuticals, Inc. (MRNS) Receives Consensus Rating of “Hold” from Analysts” was first published by sleekmoney and is owned by of sleekmoney. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at http://sleekmoney.com/marinus-pharmaceuticals-inc-mrns-receives-consensus-rating-of-hold-from-analysts/1659800.html.
Marinus Pharmaceuticals (NASDAQ:MRNS) opened at 1.25 on Tuesday. The firm has a 50-day moving average of $1.16 and a 200 day moving average of $1.34. The company’s market cap is $24.63 million. Marinus Pharmaceuticals has a 52-week low of $0.82 and a 52-week high of $6.76.
A hedge fund recently raised its stake in Marinus Pharmaceuticals stock. Sphera Funds Management LTD. raised its position in shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 14.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,340,588 shares of the biopharmaceutical company’s stock after buying an additional 169,945 shares during the period. Sphera Funds Management LTD. owned 6.87% of Marinus Pharmaceuticals worth $2,440,000 as of its most recent filing with the SEC. 30.88% of the stock is currently owned by institutional investors and hedge funds.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/marinus-pharmaceuticals-inc-mrns-receives-consensus-rating-of-hold-from-analysts/1659800.html
Receive News & Ratings for Marinus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.